You are here

Wider Use Sought for Xarelto (Rivaroxaban)

Anticoagulant drug rejected for ACS patients earlier this month (Mar. 8)

According to a Reuters report, two phase III trials have been initiated to expand the use of the anticoagulant drug Xarelto (rivaroxaban). One study is evaluating the drug in patients with chronic heart failure and significant coronary artery disease, and the other study involves patients receiving percutaneous coronary intervention (stents).

Xarelto was co-developed by Bayer in Germany and Johnson & Johnson in the U.S. The drug is already approved for several uses, including stroke prevention in patients with atrial fibrillation.

Earlier this month, the FDA denied approval for wider use of Xarelto to reduce the risk of heart attacks and strokes in patients with acute coronary syndrome.

Sources: Reuters; March 8, 2013; and Reuters; March 4, 2013.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time